Microbot Medical (MBOT) said Wednesday that robotic endovascular procedures using its Liberty robotic system are feasible and significantly minimize radiation exposure, based on data from a study.
According to the study, successful robotic navigation was achieved in 20 cases, meeting its primary endpoint, the company said.
The study also resulted in a mean 92% reduction in radiation exposure.
The company said it may now move to building commercial capabilities and launch preparation, according to its President and CEO Harel Gadot.
Microbot Medical shares were up over 33% in premarket trading Wednesday.
Price: 1.86, Change: +0.47, Percent Change: +33.80